• Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department
Main Menu
  • Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department

Yumanity Therapeutics

790 Memorial Drive
Cambridge, MA 02139
Drug Discovery
790 Memorial Drive
Cambridge, MA 02139
www.yumanity.com

Description

Yumanity Therapeutics is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The focus of the privately held company is neurodegenerative diseases, including Alzheimer‰’s disease, Parkinson‰’s disease and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig‰’s disease. The company‰’s proprietary platforms have already identified one potential new target for treating Parkinson‰’s disease, and Yumanity Therapeutics is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer‰’s disease and ALS.

Source: https://www.linkedin.com/company/9549553/

Company Size: 11-50 employees

Connect

  • Twitter URL
  • LinkedIn URL

Contact Us

CMU Computational Biology Department
5000 Forbes Ave
Pittsburgh, PA 15213
(412) 268-4671
social@cbd.cmu.edu

Legal Info

Follow our Twitter list of companies!

My Tweets

Computational Biology Career Events

No upcoming events

Copyright © 2018 Carnegie Mellon University. All Rights Reserved

Login

Lost your password?